Artiva Biotherapeutics, Inc.
ARTV
$5.52
-$0.28-4.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -29.06% | -23.21% | -19.12% | -45.46% | -34.15% |
| Total Depreciation and Amortization | 8.47% | 5.58% | 6.30% | 6.98% | 3.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.66% | -42.74% | -70.80% | 1.76% | -37.11% |
| Change in Net Operating Assets | 1,412.54% | -87.01% | -48,614.29% | 50.70% | 71.39% |
| Cash from Operations | -0.52% | -65.37% | -67.94% | -31.52% | -37.24% |
| Capital Expenditure | -557.81% | -525.00% | -127.37% | -2,738.89% | 89.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,924.94% | 112.93% | 1,123.22% | 6.96% | 55.61% |
| Cash from Investing | 1,760.46% | 112.46% | 1,465.75% | 1.93% | 63.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3.03% | 15.79% | 57.69% | -- | -- |
| Issuance of Common Stock | -100.00% | -100.00% | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 103.80% | 100.00% | -- | -102.08% |
| Cash from Financing | -303.33% | -100.02% | 95.54% | -- | -103.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 107.62% | -113.68% | 86.15% | -81.58% | -26.37% |